In 2009, the UK’s National Institute for Health and Clinical Excellence (NICE) issued supplementary advice that its Appraisal Committees are to consider when assessing treatments that extend life at the end of life. This includes an option for approving such treatments for use in the NHS if certain criteria are met, even if base case cost-effectiveness estimates exceed the range usually considered acceptable.
Recent reforms to the National Health Service (NHS) in England include important changes in the regulation of prices for new medicines. From January 2014, the existing Pharmaceutical Pricing Regulation Scheme (PPRS) will be replaced by “value based pricing” (VBP) for branded medicines sold to the NHS. This will apply only to new medicines; those marketed before 2014 will continue to be governed by the PPRS.
This report examines and makes suggestions for the appropriate use of health technology assessment (HTA) in emerging markets. In particulary, it considers how the stage of development of the health care system affects the relevance and appropriate use of various types of HTA. The approach developed then is used to analyse the options for Brazil, China and Taiwan.
Mestre-Ferrandiz, J., Puig-Peiro, R. and Towse, A.
Ten member companies of the EFPIA HTA Task Force commissioned OHE consulting to provide research, data and analysis that would enable EFPIA both to support and develop its policy position and to contribute positively to the emerging dialogue around the development of HTA within Europe.
Johannesson, M., Jonsson, B., Jonsson, L., Kobelt, G. and Zethraeus, N.
In this Briefing, five leading European experts in health economics provide a comprehensive international review of changes in health economic evaluation and the reasons for them. The authors express concern that the basis for health care decision making today has evolved away from the societal perspective of cost benefit analysis to the payer perspective of cost-effectiveness analysis. Most voluntary and mandatory guidelines for evaluating medical innovation now encourage or require this narrower, budget-based payer perspective. As a result, they argue, decisions often ar
Perhaps best known for his work in cost-benefit analysis, Alan Williams was a man of principle who developed guiding values in health care economics that embraced and encouraged active intellectual engagement and progression. He was concerned with the philosophical and ethical issues that underpin decision making and his courageous intellectual battles bore new ideas and revised ideology.
This compilation of papers and further discussions arising from OHE's Alan Williams tribute conference provides an analysis of the evolution and current status of key concepts in the field.
For over a decade, the OHE website included a popular interactive e-source, The Economics of Health Care, focusing on the UK and aimed at post-16 students of economic courses. Because the details of how the NHS is organised have changed considerably, we have moved this material to the archive. We continue to make them available because the basic concepts of health economics and the types of issues the NHS faces have not changed.
In June 2006, a conference entitled Better Analysis for Better Decisions: Bridging the Gap Between Economic Evaluation and Healthcare Decision-Making was held at McMaster University in honour of the late Bernie O’Brien. The papers presented by leading health economists were reviews of the use of economic evaluation in the UK, Canada and USA, and more methodologically focused contributions.
The reviews of the experience in the three countries suggest that economic analysis is playing an increasingly important role in health sector decision making.
Whilst companies routinely conduct post-marketing surveillance studies to collect data on adverse events, the focus of this report is on ‘post-launch’ studies conducted to collect information about health outcomes, including pharmacoeconomics data. By ‘post-launch’, we mean that they are undertaken after a drug has entered the market.